GLP-1 Therapies Newsletter
Issue #25February 23, 20267 studies

GLP-1 drugs linked to 20% lower dementia risk in diabetic kidney patients

GLP-1 drugs like semaglutide and tirzepatide have transformed diabetes and obesity treatment. But this week's research reveals their effects extend far beyond blood sugar—from protecting the brain to healing bones, with some surprising side effects along the way.

🧠 GLP-1 drugs may protect against dementia in high-risk patients

  • Diabetic patients with chronic kidney disease who took GLP-1 drugs had 20% lower dementia risk and 24% lower Alzheimer's risk compared to those on DPP-4 inhibitors

  • The analysis included patients from 67 healthcare organizations across the US, following them for up to 5 years

  • No significant differences were found for other neurodegenerative conditions like Parkinson's disease or vascular dementia

Why it matters: Patients with both diabetes and kidney disease face exceptionally high dementia risk due to vascular problems and chronic inflammation—suggesting GLP-1 drugs might offer brain protection beyond their metabolic benefits.

🎖️ Top 10% journal 🔗 Nephrol Dial Transplant 🗓️ Feb 16

Key Findings

🦴 Surprising bone healing benefits in foot surgery

  • Diabetic patients on GLP-1 drugs had 15.9% bone fusion failure rates after ankle surgeries compared to 20.2% in matched controls

  • Early hardware removal after ankle fracture repair was also significantly lower in GLP-1 users

  • No increased infection risk was observed despite concerns about delayed healing

💡 GLP-1 drugs may actually improve bone healing outcomes, contradicting concerns about surgical complications.
🔗 Cureus 🗓️ Feb 17

⚖️ Weight regain reveals gut-brain connections

  • 71.4% of women regained an average of 5.1 kg within 12 weeks of stopping semaglutide, with 78.5% reporting appetite rebounds

  • Animal studies showed gut bacteria changes and decreased bile acid levels after drug withdrawal

  • Brain appetite control pathways rebounded while some metabolic improvements persisted

💡 The rapid return of hunger and weight after stopping GLP-1 drugs suggests these medications fundamentally alter gut-brain communication.
🥉 Top 5% journal 🔗 Diabetes, obesity & metabolism 🗓️ Feb 18

🔍 Eye complications emerge as rare but real risk

  • GLP-1 drug users had 2.56 times higher risk of developing vision-threatening eye condition NAION within one year

  • Risk was highest in the first 6 months and among patients under 50, men, and smokers

  • The condition affected 18.5 per 100,000 GLP-1 users versus 7.2 per 100,000 control patients

💡 While rare, this serious eye complication adds to growing awareness that rapid blood sugar improvements can have unexpected consequences.
🥇 Top 1% journal 🔗 Diabetes care 🗓️ Feb 17

🧬 Dual-action drugs show superior weight loss

  • Tirzepatide and other dual/triple hormone agonists produced 11.47 kg more weight loss than placebo in meta-analysis of 3,236 participants

  • These newer drugs also improved blood sugar and waist circumference more than single-hormone GLP-1 drugs

  • Higher rates of nausea, vomiting, and treatment discontinuation were observed

💡 Next-generation drugs targeting multiple hormone pathways may offer greater benefits but with increased side effects.
Top 50% journal 🔗 Cardiology in review 🗓️ Feb 19

🚭 Mental health benefits extend beyond metabolism

  • Patients with severe mental disorders on GLP-1 drugs had 52% lower suicide attempt risk and 39% lower self-harm risk

  • All-cause mortality was 50% lower, and substance use disorders were 24% lower in the treatment group

  • Analysis included 21,984 matched pairs of patients with psychotic disorders

💡 GLP-1 drugs appear to provide broad mental health protection, possibly through brain pathways beyond their metabolic effects.
🎖️ Top 10% journal 🔗 Journal of psychopharmacology (Oxford, England) 🗓️ Feb 16

⚠️ Gastric emptying risks persist despite precautions

  • A patient who followed standard fasting guidelines and skipped one weekly semaglutide dose still had substantial stomach contents during endoscopy

  • The same patient had previously undergone similar procedures successfully with identical precautions

  • Case highlights unpredictable nature of GLP-1 drugs' effects on stomach emptying

💡 Standard pre-procedure fasting may not be sufficient for patients on GLP-1 drugs, potentially requiring extended liquid diets.
🔗 A&A practice 🗓️ Feb 18

Implications

This week's research reveals GLP-1 drugs as remarkably pleiotropic medications with effects extending far beyond diabetes and weight loss. While they show promise for brain protection, bone healing, and mental health, new safety signals around vision and gastric complications emphasize the need for careful patient monitoring as these drugs become increasingly widespread.

Studies in this issue

Primary sources used for this newsletter.

  1. GLP-1 receptor drugs lower dementia and Alzheimer’s risk in diabetic patients with kidney disease
    main storyNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2026-02-16PMID 41697144
  2. Use of Glucagon-Like Peptide-1 Therapy Around Surgery and Recovery Results in Adult Foot and Ankle Operations
    key findingCureus2026-02-17PMID 41700259
  3. Effects of Dual and Triple Incretin Treatments on Weight in Overweight or Obese People
    key findingCardiology in review2026-02-19PMID 41711462
  4. Incretin therapy linked to self-harm behaviors in people with mental health conditions
    key findingJournal of psychopharmacology (Oxford, England)2026-02-16PMID 41693095
  5. Weight regain after semaglutide treatment in women with obesity linked to gut bacteria, bile acid changes, and brain signals
    key findingDiabetes, obesity & metabolism2026-02-18PMID 41705640
  6. Unexpected Stomach Contents After Standard Fasting Despite Stopping Semaglutide: A Case Report
    key findingA&A practice2026-02-18PMID 41705849
  7. Glucagon-Like Peptide 1 Receptor Agonists and Risk of Sudden Optic Nerve Damage in People with Type 2 Diabetes
    key findingDiabetes care2026-02-17PMID 41701611

Continue reading

All GLP-1 Therapies issues